The choice of potential technology transfer partners can be bewildering. Understand how factors such as consolidation, outsourcing, as well as equipment and material challenges should be taken into consideration when making this decision.
Some of the challenges in early stages of a pharmaceutical are a limited supply of protein to use in formulation screening studies, and a need to obtain stability data quickly to initiate tox studies. In this poster, scientists at Catalent Biologics outline a method utilizing a high-throughput, microwell plate platform to economically screen a mAb in 96 formulations.
Conducting a pilot formulation study at the early drug substance development stage can make things considerably easier at the manufacturing stage. Read how Catalent Biologics utilizes automation, specifically the Uncle platform, during formulation development.
Catalent Biologics is your one integrated partner with expertise to get your biologic to market faster. We have the passion to help you accelerate, simplify, and derisk your next biologic from development and manufacturing, to fill/finish, clinical supply, and commercial launch.